Key result
Hesperidin attenuates doxorubicin-induced cardiotoxicity in rats by normalizing antioxidant and cardiac biomarkers.
Why the study?
Doxorubicin use is restricted by cardiotoxicity linked to oxidative stress, and enhancing antioxidant capacity with agents such as hesperidin represents a promising cardioprotective approach.
Does oral hesperidin co-treatment attenuate doxorubicin-induced biochemical, inflammatory, apoptotic, and histopathological cardiotoxicity in male Wistar rats?
Does oral hesperidin co-treatment attenuate doxorubicin-induced biochemical, inflammatory, apoptotic, and histopathological cardiotoxicity in male Wistar rats?
Answers are grounded in this paper and cite their sources.
In a rat model, oral hesperidin co-treatment mitigated doxorubicin-induced cardiotoxicity through antioxidant, anti-inflammatory, and antiapoptotic mechanisms.
Background: Doxorubicin (DOX), an anthracycline antibiotic, is a powerful chemotherapeutic agent effective against multiple types of cancer, particularly lung, breast, bladder and hematologic neoplasia (lymphomas and leukemia). However, its therapeutic usage is restricted by its known cardiotoxicity, which is associated with the production of oxidative stress. Enhancing antioxidant capacity represents a promising approach to mitigate DOX-induced cardiotoxicity. Hesperidin (HES), a citrus bioflavonoid, possesses several pharmacological effects, such as anti-inflammatory and antioxidant characteristics. Aim: This study was designed to evaluate the cardiotoxicity of DOX and assess the possible cardioprotective role of HES. Methods: Groups of Wistar rats were either treated with DOX (4 mg/kg. bw., once a week for five consecutive weeks, intraperitoneally) or received co-treatment with HES (100 mg/kg. bw./day in distilled water, 5 days in a week for five consecutive weeks, administered orally). Heart and blood samples were obtained for histological, immunohistochemical, and biochemical assessments. Furthermore, DOX-induced oxidative stress and substantially reduced the levels of antioxidant enzymes, including Glutathione peroxidase (GPX), Superoxide dismutase (SOD), and Catalase (CAT). Histopathologically, DOX caused severe Zenker's necrosis, cardiomyocyte disarray, sarcoplasmic vacuolizations, cardiomyocyte congestion, and inflammatory cell infiltration. Immunohistochemically, DOX exhibited extensive apoptosis, as indicated by strong positive immuno-localization against anti-caspase-3 antibody. In contrast, co-treatment with HES protected cardiac tissues against cardiotoxicity of DOX, as indicated by the amelioration of histological abnormalities and the normalization of biochemical values. Conclusion: We can conclude that DOX induces severe cardiotoxicity characterized by oxidative stress, inflammation, pathological alterations, and apoptosis. Co-treatment with HES demonstrates significant cardioprotective effects by virtue of its potent anti-inflammatory, antioxidant, cytoprotective, and antiapoptotic characteristics.
No takes yet. Share an insight, caveat, or question.
Alharbi et al. (2023) studied Doxorubicin-induced cardiotoxicity (n=40). Hesperidin vs. Doxorubicin 4 mg/kg bw intraperitoneally once every week for 5 consecutive weeks alone, or untreated control was evaluated on Biochemical markers of oxidative stress (GPX, CAT, SOD), cardiac injury (Troponin I, CK-Total, CK-MB, LDH, AST), pro-inflammatory cytokines (IFN-γ, IL-1β, TNF-α), and myocardial histopathology/caspase-3 immunoreactivity (p=<0.05). Hesperidin co-treatment ameliorated doxorubicin-induced cardiotoxicity in rats by normalizing antioxidant enzymes, cardiac biomarkers, and cytokines.
Synapse has enriched 10 related papers. Consider them for comparative context: